| Role |
Name |
Disclosure |
Details |
| Author | Malvinder S Parmar, MB, MS, FRCP(C), FACP, Assistant Professor (VPT), Faculty of Medicine, University of Ottawa; Associate Professor, Department of Internal Medicine, Northern Ontario School of Medicine, Timmins and District Hospital, Canada | Nothing to disclose | Details | | Medical Editor | Philip Schulman, MD, Chief, Medical Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center; Clinical Professor, Department of Medicine, New York University School of Medicine | celgene Amgen genetech/idec | Details | | Pharmacy Editor | Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine | Nothing to disclose | Details | | Managing Editor | Benjamin Movsas, MD, Vice-Chairman, Department of Radiation Oncology, Fox Chase Cancer Center | Nothing to disclose | Details | | CME Editor | Rajalaxmi McKenna, MD, FACP, Consulting Staff, Department of Medicine, Southwest Medical Consultants, SC, Good Samaritan Hospital, Advocate Health Systems | Nothing to disclose | Details | | Chief Editor | Jules E Harris, MD, Visiting Professor of Medicine, Division of Hematology/Medical Oncology, Department of Internal Medicine, University of Arizona College of Medicine at Tucson; Consulting Staff, Arizona Cancer Center | GlobeImmune Amplimed | Details |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Benjamin Movsas, Managing Editor |
The contributor discloses no conflict of interest. |
|